Nifty
Sensex
:
:
15746.50
52574.46
63.15 (0.40%)
230.01 (0.44%)

Pharmaceuticals & Drugs - API

Rating :
56/99

BSE: 500288 | NSE: MOREPENLAB

62.90
21-Jun-2021
  • Open
  • High
  • Low
  • Previous Close
  •  61.10
  •  64.35
  •  61.10
  •  62.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  3083976
  •  1944.55
  •  72.40
  •  19.25

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,827.16
  • 29.12
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,921.40
  • N/A
  • 6.66

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 34.54%
  • 3.72%
  • 42.97%
  • FII
  • DII
  • Others
  • 0.68%
  • 2.70%
  • 15.39%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.09
  • 11.95
  • 12.04

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 28.07
  • 2.17
  • 1.14

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 21.28
  • 4.31

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 30.74
  • 32.35
  • 26.07

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.03
  • 4.53
  • 3.82

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.25
  • 15.00
  • 13.02

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Var%
Dec 20
Dec 19
Var%
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Net Sales
286.60
206.60
38.72%
307.42
230.06
33.63%
336.39
213.43
57.61%
257.64
202.98
26.93%
Expenses
256.20
187.78
36.44%
277.63
214.75
29.28%
304.64
198.37
53.57%
231.07
183.65
25.82%
EBITDA
30.40
18.83
61.44%
29.79
15.30
94.71%
31.75
15.06
110.82%
26.57
19.33
37.45%
EBIDTM
10.61%
9.11%
9.69%
6.65%
9.44%
7.05%
10.31%
9.52%
Other Income
4.16
1.79
132.40%
2.84
4.60
-38.26%
3.73
2.81
32.74%
1.33
0.28
375.00%
Interest
-0.05
0.62
-
1.27
0.54
135.19%
0.29
0.39
-25.64%
0.29
0.43
-32.56%
Depreciation
6.98
8.63
-19.12%
7.56
8.54
-11.48%
7.68
8.24
-6.80%
8.06
11.50
-29.91%
PBT
27.64
11.36
143.31%
23.80
10.82
119.96%
27.52
9.24
197.84%
19.55
7.68
154.56%
Tax
0.87
0.34
155.88%
0.01
0.01
0.00%
0.35
5.15
-93.20%
0.19
0.02
850.00%
PAT
26.76
11.02
142.83%
23.79
10.82
119.87%
27.17
4.09
564.30%
19.36
7.66
152.74%
PATM
9.34%
5.33%
7.74%
4.70%
8.08%
1.92%
7.52%
3.77%
EPS
0.59
0.25
136.00%
0.53
0.24
120.83%
0.60
0.09
566.67%
0.43
0.17
152.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
1,188.05
853.07
768.54
606.51
595.47
485.08
400.64
366.85
325.92
289.34
228.30
Net Sales Growth
39.27%
11.00%
26.72%
1.85%
22.76%
21.08%
9.21%
12.56%
12.64%
26.74%
 
Cost Of Goods Sold
780.54
524.19
479.12
361.28
358.35
293.33
238.62
209.04
193.53
178.07
142.68
Gross Profit
407.51
328.87
289.42
245.23
237.12
191.76
162.02
157.81
132.39
111.27
85.62
GP Margin
34.30%
38.55%
37.66%
40.43%
39.82%
39.53%
40.44%
43.02%
40.62%
38.46%
37.50%
Total Expenditure
1,069.54
784.55
701.02
541.78
534.09
423.52
352.41
317.95
294.97
270.11
222.53
Power & Fuel Cost
-
12.56
13.18
11.08
9.84
7.64
7.41
8.42
8.96
9.82
7.69
% Of Sales
-
1.47%
1.71%
1.83%
1.65%
1.57%
1.85%
2.30%
2.75%
3.39%
3.37%
Employee Cost
-
109.91
95.36
76.53
69.69
58.29
48.79
45.08
39.17
36.05
30.52
% Of Sales
-
12.88%
12.41%
12.62%
11.70%
12.02%
12.18%
12.29%
12.02%
12.46%
13.37%
Manufacturing Exp.
-
48.92
31.28
16.21
22.36
13.33
12.68
12.23
11.33
10.20
11.40
% Of Sales
-
5.73%
4.07%
2.67%
3.76%
2.75%
3.16%
3.33%
3.48%
3.53%
4.99%
General & Admin Exp.
-
36.47
36.14
28.52
18.11
18.14
15.89
16.62
13.86
14.37
12.72
% Of Sales
-
4.28%
4.70%
4.70%
3.04%
3.74%
3.97%
4.53%
4.25%
4.97%
5.57%
Selling & Distn. Exp.
-
40.11
32.73
30.04
25.79
23.45
21.40
19.55
20.40
15.85
11.26
% Of Sales
-
4.70%
4.26%
4.95%
4.33%
4.83%
5.34%
5.33%
6.26%
5.48%
4.93%
Miscellaneous Exp.
-
12.39
13.20
18.11
29.95
9.35
7.61
7.01
7.72
5.75
11.26
% Of Sales
-
1.45%
1.72%
2.99%
5.03%
1.93%
1.90%
1.91%
2.37%
1.99%
2.74%
EBITDA
118.51
68.52
67.52
64.73
61.38
61.56
48.23
48.90
30.95
19.23
5.77
EBITDA Margin
9.98%
8.03%
8.79%
10.67%
10.31%
12.69%
12.04%
13.33%
9.50%
6.65%
2.53%
Other Income
12.06
9.48
3.67
3.72
3.72
1.20
1.37
1.22
2.87
1.18
1.04
Interest
1.80
1.98
2.11
4.36
7.56
10.50
8.66
9.92
11.63
7.96
6.27
Depreciation
30.28
36.91
39.90
34.32
33.90
35.20
38.67
45.84
45.80
48.06
48.16
PBT
98.51
39.11
29.18
29.77
23.63
17.06
2.28
-5.64
-23.61
-35.61
-47.62
Tax
1.42
5.53
0.34
0.00
0.00
-0.13
0.14
0.01
-0.01
0.06
-0.69
Tax Rate
1.44%
14.14%
1.17%
0.00%
0.00%
-1.03%
6.14%
-0.36%
0.05%
-0.25%
1.45%
PAT
97.08
33.58
28.85
29.59
23.63
12.80
2.14
-2.77
-20.52
-23.65
-46.93
PAT before Minority Interest
97.07
33.58
28.84
29.77
23.63
12.80
2.14
-2.75
-20.52
-23.63
-46.93
Minority Interest
-0.01
0.00
0.01
-0.18
0.00
0.00
0.00
-0.02
0.00
-0.02
0.00
PAT Margin
8.17%
3.94%
3.75%
4.88%
3.97%
2.64%
0.53%
-0.76%
-6.30%
-8.17%
-20.56%
PAT Growth
189.01%
16.40%
-2.50%
25.22%
84.61%
498.13%
-
-
-
-
 
EPS
2.16
0.75
0.64
0.66
0.53
0.28
0.05
-0.06
-0.46
-0.53
-1.04

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
284.06
253.09
225.94
196.26
300.28
287.48
297.11
299.88
320.40
344.05
Share Capital
89.96
89.96
89.96
89.96
209.61
209.61
209.61
209.61
209.61
209.61
Total Reserves
194.10
163.13
135.98
106.30
90.67
77.87
87.50
90.27
110.79
134.44
Non-Current Liabilities
28.42
23.38
20.20
17.80
57.47
74.00
84.65
103.91
122.05
135.01
Secured Loans
0.92
1.83
2.95
1.38
43.41
62.27
74.78
94.65
98.85
114.37
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
15.04
14.32
Long Term Provisions
23.82
19.01
14.42
13.59
11.34
9.22
7.82
7.17
5.73
3.90
Current Liabilities
351.44
339.17
340.12
324.86
166.56
127.92
108.14
102.73
104.95
102.78
Trade Payables
172.30
168.15
174.88
124.88
115.33
84.96
68.60
56.81
64.98
59.79
Other Current Liabilities
165.06
160.64
163.90
198.65
47.04
39.87
37.58
45.22
38.96
41.11
Short Term Borrowings
11.36
8.99
0.00
0.00
0.00
2.23
1.19
0.00
0.00
0.00
Short Term Provisions
2.72
1.39
1.33
1.33
4.19
0.86
0.77
0.70
1.01
1.88
Total Liabilities
663.46
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98
581.40
Net Block
216.37
236.21
264.29
271.80
296.72
322.48
368.08
409.46
451.86
496.02
Gross Block
752.55
887.76
997.60
1,026.96
1,018.43
1,009.35
1,004.61
1,000.44
997.38
997.96
Accumulated Depreciation
536.18
651.55
733.31
755.15
721.72
686.87
636.53
590.98
545.52
501.94
Non Current Assets
291.29
315.71
342.37
346.34
366.53
374.42
393.18
415.00
457.37
501.38
Capital Work in Progress
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Non Current Investment
1.08
0.00
0.00
0.00
0.00
0.00
0.00
3.87
3.87
3.97
Long Term Loans & Adv.
73.55
79.22
77.81
73.69
69.82
51.94
25.10
1.67
1.64
1.39
Other Non Current Assets
0.28
0.28
0.27
0.85
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
372.18
299.47
243.44
191.95
157.15
114.58
96.32
91.09
89.61
80.02
Current Investments
0.00
0.02
0.22
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
138.48
94.20
76.89
64.66
42.14
37.11
33.30
37.05
38.66
34.70
Sundry Debtors
137.68
133.75
121.85
92.95
87.94
56.14
42.67
39.11
35.15
29.64
Cash & Bank
38.88
32.21
5.95
7.59
4.36
8.85
9.11
5.53
4.51
2.58
Other Current Assets
57.14
7.86
5.62
4.71
22.71
12.48
11.24
9.40
11.29
13.10
Short Term Loans & Adv.
51.16
31.43
32.92
22.03
16.77
9.34
8.23
6.23
9.60
10.30
Net Current Assets
20.73
-39.70
-96.68
-132.92
-9.41
-13.34
-11.82
-11.64
-15.34
-22.76
Total Assets
663.47
615.18
585.81
538.29
523.68
489.00
489.50
506.09
546.98
581.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
11.02
17.37
63.41
40.73
50.07
50.70
33.52
33.64
27.11
11.13
PBT
39.11
29.18
29.77
23.04
17.06
2.28
-5.64
-23.60
-35.61
-47.62
Adjustment
36.63
40.32
38.64
41.40
45.69
47.32
55.76
56.80
55.99
54.44
Changes in Working Capital
-58.84
-51.78
-5.00
-23.72
-8.41
1.23
-19.50
-2.64
-5.25
3.63
Cash after chg. in Working capital
16.89
17.71
63.41
40.73
54.34
50.83
30.62
30.56
15.13
10.45
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-5.88
-0.34
0.00
0.00
0.13
-0.13
0.01
0.01
-0.06
0.68
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
-4.40
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-12.46
-13.05
-26.93
-13.60
-27.30
-31.65
-0.80
-2.83
-3.35
-4.05
Net Fixed Assets
135.60
113.16
31.96
-8.08
-7.02
-4.73
-4.09
-2.87
0.60
-2.41
Net Investments
-1.07
0.20
-0.22
0.00
0.25
0.00
3.87
0.00
0.10
0.00
Others
-146.99
-126.41
-58.67
-5.52
-20.53
-26.92
-0.58
0.04
-4.05
-1.64
Cash from Financing Activity
5.49
-0.44
-37.77
-23.72
-27.26
-19.31
-29.14
-29.79
-21.83
-5.60
Net Cash Inflow / Outflow
4.04
3.88
-1.29
3.40
-4.49
-0.26
3.58
1.02
1.93
1.48
Opening Cash & Equivalents
9.60
5.72
7.00
3.60
8.85
9.11
5.53
4.51
2.58
1.10
Closing Cash & Equivalent
13.64
9.60
5.72
7.00
4.36
8.85
9.11
5.53
4.51
2.58

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
6.32
5.63
5.02
4.36
4.02
3.73
3.95
4.01
4.46
4.99
ROA
5.25%
4.80%
5.30%
4.45%
2.53%
0.44%
-0.55%
-3.90%
-4.19%
-7.84%
ROE
12.50%
12.04%
14.10%
12.54%
7.35%
1.24%
-1.54%
-10.77%
-11.12%
-18.99%
ROCE
10.25%
10.01%
14.05%
10.18%
6.29%
2.90%
1.80%
-2.09%
-3.40%
-8.22%
Fixed Asset Turnover
1.04
0.82
0.60
0.58
0.49
0.41
0.37
0.33
0.29
0.23
Receivable days
58.07
60.70
64.63
55.44
53.22
44.17
40.16
40.83
40.35
42.17
Inventory Days
49.78
40.63
42.59
32.73
29.27
31.48
34.55
41.63
45.68
52.36
Payable days
79.06
88.85
103.38
82.97
83.88
76.01
67.69
69.30
75.59
101.91
Cash Conversion Cycle
28.78
12.48
3.85
5.20
-1.39
-0.36
7.02
13.16
10.44
-7.39
Total Debt/Equity
0.47
0.52
0.06
0.25
0.22
0.28
0.30
0.37
0.38
0.39
Interest Cover
20.71
14.83
7.83
4.13
2.21
1.26
0.72
-0.77
-1.96
-6.59

News Update:


  • Morepen Laboratories approves Rs 433 crore incoming investment from Corinth and promoters
    21st May 2021, 09:15 AM

    The meeting of the shareholders of the company was held on May 20, 2021 through video conferencing and other audio-visual means

    Read More
  • Morepen Laboratories gets nod to raise over Rs 433 crore
    28th Apr 2021, 12:46 PM

    The board of directors of the company considered and approved issue and allotment of up to 10.85 crore equity shares on a preferential basis

    Read More
  • SAT sets aside Sebi's order in Morepen Laboratories case
    27th Apr 2021, 12:58 PM

    Sebi, in September 2019, had prohibited Morepen Laboratories from the capital market for one year

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.